ES2235461T3 - Acido n,n'-bis (2-hidroxibencil)etilendiamina-n,n'-diacetico y sales de sodio de este para terapia quelante de hierro. - Google Patents

Acido n,n'-bis (2-hidroxibencil)etilendiamina-n,n'-diacetico y sales de sodio de este para terapia quelante de hierro.

Info

Publication number: ES2235461T3
Authority: ES; Spain
Prior art keywords: iron; composition; salt; acid; disease
Prior art date: 1998-02-04
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Expired - Lifetime

Application number

ES99905716T

Other languages

English (en)

Spanish (es)

Inventor

Raymond J. Bergeron, Jr.

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

University of Florida

University of Florida Research Foundation Inc

Original Assignee

University of Florida

University of Florida Research Foundation Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-02-04

Filing date

1999-02-03

Publication date

2005-07-01

1999-02-03 Application filed by University of Florida, University of Florida Research Foundation Inc filed Critical University of Florida

2005-07-01 Application granted granted Critical

2005-07-01 Publication of ES2235461T3 publication Critical patent/ES2235461T3/es

2019-02-03 Anticipated expiration legal-status Critical

Status Expired - Lifetime legal-status Critical Current

Links

239000002253 acid Substances 0.000 title claims description 20
238000002560 therapeutic procedure Methods 0.000 title abstract description 5
159000000000 sodium salts Chemical class 0.000 title description 2
238000010409 ironing Methods 0.000 title 1
230000029058 respiratory gaseous exchange Effects 0.000 title 1
XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims abstract description 177
229910052742 iron Inorganic materials 0.000 claims abstract description 84
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 42
238000007920 subcutaneous administration Methods 0.000 claims abstract description 41
201000010099 disease Diseases 0.000 claims abstract description 40
206010065973 Iron Overload Diseases 0.000 claims abstract description 26
OEUUFNIKLCFNLN-LLVKDONJSA-N chembl432481 Chemical compound OC(=O)[C@@]1(C)CSC(C=2C(=CC(O)=CC=2)O)=N1 OEUUFNIKLCFNLN-LLVKDONJSA-N 0.000 claims abstract description 7
239000000203 mixture Substances 0.000 claims description 62
238000000034 method Methods 0.000 claims description 29
238000011282 treatment Methods 0.000 claims description 27
150000003839 salts Chemical class 0.000 claims description 24
239000002738 chelating agent Substances 0.000 claims description 21
239000007924 injection Substances 0.000 claims description 20
238000002347 injection Methods 0.000 claims description 20
239000000546 pharmaceutical excipient Substances 0.000 claims description 20
150000001875 compounds Chemical class 0.000 claims description 18
238000002360 preparation method Methods 0.000 claims description 15
QXNVGIXVLWOKEQ-UHFFFAOYSA-N Disodium Chemical class [Na][Na] QXNVGIXVLWOKEQ-UHFFFAOYSA-N 0.000 claims description 14
KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 14
238000004519 manufacturing process Methods 0.000 claims description 11
238000010254 subcutaneous injection Methods 0.000 claims description 11
239000007929 subcutaneous injection Substances 0.000 claims description 11
125000006290 2-hydroxybenzyl group Chemical group [H]OC1=C(C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 claims description 9
208000018565 Hemochromatosis Diseases 0.000 claims description 8
241000124008 Mammalia Species 0.000 claims description 7
239000008194 pharmaceutical composition Substances 0.000 claims description 7
208000031856 Haemosiderosis Diseases 0.000 claims description 6
208000031886 HIV Infections Diseases 0.000 claims description 4
206010028980 Neoplasm Diseases 0.000 claims description 4
201000011510 cancer Diseases 0.000 claims description 4
201000004792 malaria Diseases 0.000 claims description 4
208000012902 Nervous system disease Diseases 0.000 claims description 3
208000025966 Neurological disease Diseases 0.000 claims description 3
206010052779 Transplant rejections Diseases 0.000 claims description 3
230000010410 reperfusion Effects 0.000 claims description 3
230000006378 damage Effects 0.000 claims description 2
208000035475 disorder Diseases 0.000 claims description 2
230000003902 lesion Effects 0.000 claims description 2
229940102223 injectable solution Drugs 0.000 claims 3
229940102213 injectable suspension Drugs 0.000 claims 3
206010063837 Reperfusion injury Diseases 0.000 claims 1
230000000926 neurological effect Effects 0.000 claims 1
GRUVVLWKPGIYEG-UHFFFAOYSA-N 2-[2-[carboxymethyl-[(2-hydroxyphenyl)methyl]amino]ethyl-[(2-hydroxyphenyl)methyl]amino]acetic acid Chemical compound C=1C=CC=C(O)C=1CN(CC(=O)O)CCN(CC(O)=O)CC1=CC=CC=C1O GRUVVLWKPGIYEG-UHFFFAOYSA-N 0.000 abstract description 59
-1 iron overload Chemical compound 0.000 abstract description 7
125000002091 cationic group Chemical group 0.000 abstract 1
230000029142 excretion Effects 0.000 description 26
UBQYURCVBFRUQT-UHFFFAOYSA-N N-benzoyl-Ferrioxamine B Chemical compound CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN UBQYURCVBFRUQT-UHFFFAOYSA-N 0.000 description 22
239000000797 iron chelating agent Substances 0.000 description 18
229940075525 iron chelating agent Drugs 0.000 description 17
241000282693 Cercopithecidae Species 0.000 description 16
230000037396 body weight Effects 0.000 description 16
239000003981 vehicle Substances 0.000 description 15
210000002700 urine Anatomy 0.000 description 14
241000700159 Rattus Species 0.000 description 12
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
241001465754 Metazoa Species 0.000 description 9
241000288906 Primates Species 0.000 description 9
238000001802 infusion Methods 0.000 description 8
239000008389 polyethoxylated castor oil Substances 0.000 description 8
241000282676 Sapajus apella Species 0.000 description 7
210000000941 bile Anatomy 0.000 description 7
210000003608 fece Anatomy 0.000 description 7
239000000126 substance Substances 0.000 description 7
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
241000283984 Rodentia Species 0.000 description 6
239000008363 phosphate buffer Substances 0.000 description 6
239000000243 solution Substances 0.000 description 6
229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 5
238000010521 absorption reaction Methods 0.000 description 5
239000008135 aqueous vehicle Substances 0.000 description 5
MVZXTUSAYBWAAM-UHFFFAOYSA-N iron;sulfuric acid Chemical compound [Fe].OS(O)(=O)=O MVZXTUSAYBWAAM-UHFFFAOYSA-N 0.000 description 5
239000007788 liquid Substances 0.000 description 5
239000003921 oil Substances 0.000 description 5
235000019198 oils Nutrition 0.000 description 5
239000000047 product Substances 0.000 description 5
239000002904 solvent Substances 0.000 description 5
210000001519 tissue Anatomy 0.000 description 5
206010020751 Hypersensitivity Diseases 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
210000004369 blood Anatomy 0.000 description 4
239000008280 blood Substances 0.000 description 4
230000009920 chelation Effects 0.000 description 4
230000006698 induction Effects 0.000 description 4
239000007972 injectable composition Substances 0.000 description 4
239000002687 nonaqueous vehicle Substances 0.000 description 4
230000002035 prolonged effect Effects 0.000 description 4
239000000725 suspension Substances 0.000 description 4
QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
241000282412 Homo Species 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 3
ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
150000007513 acids Chemical class 0.000 description 3
239000013543 active substance Substances 0.000 description 3
208000030961 allergic reaction Diseases 0.000 description 3
210000000013 bile duct Anatomy 0.000 description 3
239000000872 buffer Substances 0.000 description 3
239000003795 chemical substances by application Substances 0.000 description 3
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
238000011161 development Methods 0.000 description 3
239000003814 drug Substances 0.000 description 3
230000000694 effects Effects 0.000 description 3
150000002148 esters Chemical class 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
238000000855 fermentation Methods 0.000 description 3
230000004151 fermentation Effects 0.000 description 3
238000009472 formulation Methods 0.000 description 3
230000002503 metabolic effect Effects 0.000 description 3
230000008569 process Effects 0.000 description 3
238000001179 sorption measurement Methods 0.000 description 3
HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
241000282668 Cebus Species 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
102000007474 Multiprotein Complexes Human genes 0.000 description 2
108010085220 Multiprotein Complexes Proteins 0.000 description 2
GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 2
ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 2
NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
LCTONWCANYUPML-UHFFFAOYSA-N Pyruvic acid Chemical compound CC(=O)C(O)=O LCTONWCANYUPML-UHFFFAOYSA-N 0.000 description 2
239000008156 Ringer's lactate solution Substances 0.000 description 2
238000000692 Student's t-test Methods 0.000 description 2
QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
125000000217 alkyl group Chemical group 0.000 description 2
239000003963 antioxidant agent Substances 0.000 description 2
235000006708 antioxidants Nutrition 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 2
150000003857 carboxamides Chemical class 0.000 description 2
238000006243 chemical reaction Methods 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
235000005911 diet Nutrition 0.000 description 2
230000037213 diet Effects 0.000 description 2
CKQQMPJQZXIYMJ-UHFFFAOYSA-N dihydrate;dihydrochloride Chemical compound O.O.Cl.Cl CKQQMPJQZXIYMJ-UHFFFAOYSA-N 0.000 description 2
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
150000007529 inorganic bases Chemical class 0.000 description 2
238000002372 labelling Methods 0.000 description 2
239000003446 ligand Substances 0.000 description 2
150000004667 medium chain fatty acids Chemical class 0.000 description 2
244000005700 microbiome Species 0.000 description 2
230000003278 mimic effect Effects 0.000 description 2
229910017604 nitric acid Inorganic materials 0.000 description 2
150000007530 organic bases Chemical class 0.000 description 2
239000002245 particle Substances 0.000 description 2
229940124531 pharmaceutical excipient Drugs 0.000 description 2
239000008055 phosphate buffer solution Substances 0.000 description 2
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
239000011780 sodium chloride Substances 0.000 description 2
238000012353 t test Methods 0.000 description 2
YAPQBXQYLJRXSA-UHFFFAOYSA-N theobromine Chemical compound CN1C(=O)NC(=O)C2=C1N=CN2C YAPQBXQYLJRXSA-UHFFFAOYSA-N 0.000 description 2
JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
230000001988 toxicity Effects 0.000 description 2
231100000419 toxicity Toxicity 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 2
239000008136 water-miscible vehicle Substances 0.000 description 2
QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
WBYWAXJHAXSJNI-VOTSOKGWSA-M .beta-Phenylacrylic acid Natural products [O-]C(=O)\C=C\C1=CC=CC=C1 WBYWAXJHAXSJNI-VOTSOKGWSA-M 0.000 description 1
BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 1
208000004998 Abdominal Pain Diseases 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
206010002091 Anaesthesia Diseases 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
238000012935 Averaging Methods 0.000 description 1
239000005711 Benzoic acid Substances 0.000 description 1
KWIUHFFTVRNATP-UHFFFAOYSA-N Betaine Natural products C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
208000006029 Cardiomegaly Diseases 0.000 description 1
208000031229 Cardiomyopathies Diseases 0.000 description 1
241000499489 Castor canadensis Species 0.000 description 1
WBYWAXJHAXSJNI-SREVYHEPSA-N Cinnamic acid Chemical compound OC(=O)\C=C/C1=CC=CC=C1 WBYWAXJHAXSJNI-SREVYHEPSA-N 0.000 description 1
235000013162 Cocos nucifera Nutrition 0.000 description 1
244000060011 Cocos nucifera Species 0.000 description 1
108700037009 Congenital atransferrinemia Proteins 0.000 description 1
102000004127 Cytokines Human genes 0.000 description 1
108090000695 Cytokines Proteins 0.000 description 1
ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
241000196324 Embryophyta Species 0.000 description 1
PIICEJLVQHRZGT-UHFFFAOYSA-N Ethylenediamine Chemical compound NCCN PIICEJLVQHRZGT-UHFFFAOYSA-N 0.000 description 1
102000008857 Ferritin Human genes 0.000 description 1
108050000784 Ferritin Proteins 0.000 description 1
238000008416 Ferritin Methods 0.000 description 1
206010016654 Fibrosis Diseases 0.000 description 1
101000766307 Gallus gallus Ovotransferrin Proteins 0.000 description 1
208000024869 Goodpasture syndrome Diseases 0.000 description 1
108010017480 Hemosiderin Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 1
YQEZLKZALYSWHR-UHFFFAOYSA-N Ketamine Chemical compound C=1C=CC=C(Cl)C=1C1(NC)CCCCC1=O YQEZLKZALYSWHR-UHFFFAOYSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
206010024870 Loss of libido Diseases 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
235000011779 Menyanthes trifoliata Nutrition 0.000 description 1
KWIUHFFTVRNATP-UHFFFAOYSA-O N,N,N-trimethylglycinium Chemical compound C[N+](C)(C)CC(O)=O KWIUHFFTVRNATP-UHFFFAOYSA-O 0.000 description 1
UEEJHVSXFDXPFK-UHFFFAOYSA-N N-dimethylaminoethanol Chemical compound CN(C)CCO UEEJHVSXFDXPFK-UHFFFAOYSA-N 0.000 description 1
HTLZVHNRZJPSMI-UHFFFAOYSA-N N-ethylpiperidine Chemical compound CCN1CCCCC1 HTLZVHNRZJPSMI-UHFFFAOYSA-N 0.000 description 1
229920002274 Nalgene Polymers 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
235000019483 Peanut oil Nutrition 0.000 description 1
QGMRQYFBGABWDR-UHFFFAOYSA-M Pentobarbital sodium Chemical compound [Na+].CCCC(C)C1(CC)C(=O)NC(=O)[N-]C1=O QGMRQYFBGABWDR-UHFFFAOYSA-M 0.000 description 1
208000012641 Pigmentation disease Diseases 0.000 description 1
239000004698 Polyethylene Substances 0.000 description 1
239000002202 Polyethylene glycol Substances 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
206010037394 Pulmonary haemorrhage Diseases 0.000 description 1
IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
239000000589 Siderophore Substances 0.000 description 1
241001137868 Streptomyces pilosus Species 0.000 description 1
KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
206010043298 Testicular atrophy Diseases 0.000 description 1
206010043391 Thalassaemia beta Diseases 0.000 description 1
102000004338 Transferrin Human genes 0.000 description 1
108090000901 Transferrin Proteins 0.000 description 1
229930003268 Vitamin C Natural products 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
208000022440 X-linked sideroblastic anemia 1 Diseases 0.000 description 1
230000003187 abdominal effect Effects 0.000 description 1
230000009471 action Effects 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
230000002411 adverse Effects 0.000 description 1
125000005907 alkyl ester group Chemical group 0.000 description 1
230000000172 allergic effect Effects 0.000 description 1
230000007815 allergy Effects 0.000 description 1
BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
229910000147 aluminium phosphate Inorganic materials 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
230000037005 anaesthesia Effects 0.000 description 1
210000003484 anatomy Anatomy 0.000 description 1
208000007502 anemia Diseases 0.000 description 1
239000004599 antimicrobial Substances 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
229960003121 arginine Drugs 0.000 description 1
230000006793 arrhythmia Effects 0.000 description 1
206010003119 arrhythmia Diseases 0.000 description 1
206010003246 arthritis Diseases 0.000 description 1
238000003556 assay Methods 0.000 description 1
208000010668 atopic eczema Diseases 0.000 description 1
201000007867 atransferrinemia Diseases 0.000 description 1
201000010788 atrophy of testis Diseases 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
230000008901 benefit Effects 0.000 description 1
229960000686 benzalkonium chloride Drugs 0.000 description 1
229960003872 benzethonium Drugs 0.000 description 1
UREZNYTWGJKWBI-UHFFFAOYSA-M benzethonium chloride Chemical compound [Cl-].C1=CC(C(C)(C)CC(C)(C)C)=CC=C1OCCOCC[N+](C)(C)CC1=CC=CC=C1 UREZNYTWGJKWBI-UHFFFAOYSA-M 0.000 description 1
235000010233 benzoic acid Nutrition 0.000 description 1
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
229960003237 betaine Drugs 0.000 description 1
230000004071 biological effect Effects 0.000 description 1
KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
229960001948 caffeine Drugs 0.000 description 1
VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
238000004364 calculation method Methods 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
150000001735 carboxylic acids Chemical class 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 description 1
229960001231 choline Drugs 0.000 description 1
235000013985 cinnamic acid Nutrition 0.000 description 1
229930016911 cinnamic acid Natural products 0.000 description 1
230000007882 cirrhosis Effects 0.000 description 1
208000019425 cirrhosis of liver Diseases 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
238000010835 comparative analysis Methods 0.000 description 1
210000002808 connective tissue Anatomy 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000013270 controlled release Methods 0.000 description 1
239000002285 corn oil Substances 0.000 description 1
235000005687 corn oil Nutrition 0.000 description 1
235000012343 cottonseed oil Nutrition 0.000 description 1
239000002385 cottonseed oil Substances 0.000 description 1
239000012043 crude product Substances 0.000 description 1
YKGMKSIHIVVYKY-UHFFFAOYSA-N dabrafenib mesylate Chemical compound CS(O)(=O)=O.S1C(C(C)(C)C)=NC(C=2C(=C(NS(=O)(=O)C=3C(=CC=CC=3F)F)C=CC=2)F)=C1C1=CC=NC(N)=N1 YKGMKSIHIVVYKY-UHFFFAOYSA-N 0.000 description 1
230000002354 daily effect Effects 0.000 description 1
239000008367 deionised water Substances 0.000 description 1
229940099217 desferal Drugs 0.000 description 1
IDDIJAWJANBQLJ-UHFFFAOYSA-N desferrioxamine B mesylate Chemical group [H+].CS([O-])(=O)=O.CC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCNC(=O)CCC(=O)N(O)CCCCCN IDDIJAWJANBQLJ-UHFFFAOYSA-N 0.000 description 1
230000006866 deterioration Effects 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
150000005690 diesters Chemical class 0.000 description 1
HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 1
238000003748 differential diagnosis Methods 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000004821 distillation Methods 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
238000009826 distribution Methods 0.000 description 1
229940079593 drug Drugs 0.000 description 1
210000001198 duodenum Anatomy 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
230000000925 erythroid effect Effects 0.000 description 1
CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
235000019441 ethanol Nutrition 0.000 description 1
229940031098 ethanolamine Drugs 0.000 description 1
229940012017 ethylenediamine Drugs 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
238000000605 extraction Methods 0.000 description 1
239000012530 fluid Substances 0.000 description 1
235000013305 food Nutrition 0.000 description 1
235000021588 free fatty acids Nutrition 0.000 description 1
239000001530 fumaric acid Substances 0.000 description 1
230000006870 function Effects 0.000 description 1
ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 description 1
230000002496 gastric effect Effects 0.000 description 1
230000002489 hematologic effect Effects 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
229960002885 histidine Drugs 0.000 description 1
XGIHQYAWBCFNPY-AZOCGYLKSA-N hydrabamine Chemical compound C([C@@H]12)CC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC[C@@]1(C)CNCCNC[C@@]1(C)[C@@H]2CCC3=CC(C(C)C)=CC=C3[C@@]2(C)CCC1 XGIHQYAWBCFNPY-AZOCGYLKSA-N 0.000 description 1
230000007062 hydrolysis Effects 0.000 description 1
238000006460 hydrolysis reaction Methods 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
208000006278 hypochromic anemia Diseases 0.000 description 1
230000006872 improvement Effects 0.000 description 1
230000001939 inductive effect Effects 0.000 description 1
230000036512 infertility Effects 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
238000013383 initial experiment Methods 0.000 description 1
229940025708 injectable product Drugs 0.000 description 1
208000014674 injury Diseases 0.000 description 1
230000031891 intestinal absorption Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
150000002506 iron compounds Chemical class 0.000 description 1
230000007794 irritation Effects 0.000 description 1
JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
229960003299 ketamine Drugs 0.000 description 1
210000003734 kidney Anatomy 0.000 description 1
229940063711 lasix Drugs 0.000 description 1
235000014666 liquid concentrate Nutrition 0.000 description 1
235000020888 liquid diet Nutrition 0.000 description 1
229910052744 lithium Inorganic materials 0.000 description 1
210000004185 liver Anatomy 0.000 description 1
210000004072 lung Anatomy 0.000 description 1
229960003646 lysine Drugs 0.000 description 1
159000000003 magnesium salts Chemical class 0.000 description 1
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
239000011976 maleic acid Substances 0.000 description 1
239000001630 malic acid Substances 0.000 description 1
235000011090 malic acid Nutrition 0.000 description 1
229960002510 mandelic acid Drugs 0.000 description 1
238000005259 measurement Methods 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
229910052751 metal Inorganic materials 0.000 description 1
239000002184 metal Substances 0.000 description 1
229940098779 methanesulfonic acid Drugs 0.000 description 1
OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 1
239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
WBYWAXJHAXSJNI-UHFFFAOYSA-N methyl p-hydroxycinnamate Natural products OC(=O)C=CC1=CC=CC=C1 WBYWAXJHAXSJNI-UHFFFAOYSA-N 0.000 description 1
LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
150000007522 mineralic acids Chemical class 0.000 description 1
230000004048 modification Effects 0.000 description 1
238000012986 modification Methods 0.000 description 1
210000001640 nerve ending Anatomy 0.000 description 1
230000007935 neutral effect Effects 0.000 description 1
231100000957 no side effect Toxicity 0.000 description 1
235000021590 normal diet Nutrition 0.000 description 1
230000004768 organ dysfunction Effects 0.000 description 1
150000007524 organic acids Chemical class 0.000 description 1
235000005985 organic acids Nutrition 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
235000006408 oxalic acid Nutrition 0.000 description 1
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
239000000312 peanut oil Substances 0.000 description 1
229960001412 pentobarbital Drugs 0.000 description 1
230000003617 peroxidasic effect Effects 0.000 description 1
229960003742 phenol Drugs 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
230000001817 pituitary effect Effects 0.000 description 1
230000001863 plant nutrition Effects 0.000 description 1
239000004033 plastic Substances 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
229920000573 polyethylene Polymers 0.000 description 1
229920001223 polyethylene glycol Polymers 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000000843 powder Substances 0.000 description 1
229940071643 prefilled syringe Drugs 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000002265 prevention Effects 0.000 description 1
238000011809 primate model Methods 0.000 description 1
MFDFERRIHVXMIY-UHFFFAOYSA-N procaine Chemical compound CCN(CC)CCOC(=O)C1=CC=C(N)C=C1 MFDFERRIHVXMIY-UHFFFAOYSA-N 0.000 description 1
229960004919 procaine Drugs 0.000 description 1
235000019260 propionic acid Nutrition 0.000 description 1
239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
201000003456 pulmonary hemosiderosis Diseases 0.000 description 1
238000000746 purification Methods 0.000 description 1
150000003212 purines Chemical class 0.000 description 1
229940107700 pyruvic acid Drugs 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
230000000306 recurrent effect Effects 0.000 description 1
238000001223 reverse osmosis Methods 0.000 description 1
229960004889 salicylic acid Drugs 0.000 description 1
229920006395 saturated elastomer Polymers 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
239000008159 sesame oil Substances 0.000 description 1
235000011803 sesame oil Nutrition 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
239000008354 sodium chloride injection Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000013222 sprague-dawley male rat Methods 0.000 description 1
238000012453 sprague-dawley rat model Methods 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008227 sterile water for injection Substances 0.000 description 1
238000011421 subcutaneous treatment Methods 0.000 description 1
238000006467 substitution reaction Methods 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
235000002906 tartaric acid Nutrition 0.000 description 1
239000011975 tartaric acid Substances 0.000 description 1
231100001044 testicular atrophy Toxicity 0.000 description 1
229960004559 theobromine Drugs 0.000 description 1
230000001225 therapeutic effect Effects 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
239000012581 transferrin Substances 0.000 description 1
150000003626 triacylglycerols Chemical class 0.000 description 1
YFTHZRPMJXBUME-UHFFFAOYSA-N tripropylamine Chemical compound CCCN(CCC)CCC YFTHZRPMJXBUME-UHFFFAOYSA-N 0.000 description 1
LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
229960000281 trometamol Drugs 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
235000019154 vitamin C Nutrition 0.000 description 1
239000011718 vitamin C Substances 0.000 description 1
239000008215 water for injection Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical & Material Sciences (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Toxicology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

ES99905716T 1998-02-04 1999-02-03 Acido n,n'-bis (2-hidroxibencil)etilendiamina-n,n'-diacetico y sales de sodio de este para terapia quelante de hierro. Expired - Lifetime ES2235461T3 (es)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US7360398P	1998-02-04	1998-02-04
US73603P		1998-02-04

Publications (1)

Publication Number	Publication Date
ES2235461T3 true ES2235461T3 (es)	2005-07-01

Family

ID=22114691

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ES99905716T Expired - Lifetime ES2235461T3 (es)	1998-02-04	1999-02-03	Acido n,n'-bis (2-hidroxibencil)etilendiamina-n,n'-diacetico y sales de sodio de este para terapia quelante de hierro.

Country Status (13)

Country	Link
US (2)	US6242492B1 (de)
EP (1)	EP1052985B1 (de)
JP (1)	JP2002502816A (de)
CN (1)	CN1227006C (de)
AT (1)	ATE285232T1 (de)
AU (1)	AU752383B2 (de)
CA (1)	CA2319255C (de)
DE (1)	DE69922787T2 (de)
ES (1)	ES2235461T3 (de)
NZ (1)	NZ506528A (de)
PT (1)	PT1052985E (de)
TR (1)	TR200002256T2 (de)
WO (1)	WO1999039706A1 (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7232830B2 (en) *	1998-06-26	2007-06-19	Elaine A Delack	Method for treatment of neurodegenerative diseases and effects of aging
JP5349722B2 (ja)	1999-10-01	2013-11-20	ディーエムアイバイオサイエンシズインコーポレイテッド	金属結合化合物およびその使用方法
US7592304B2 (en)	1999-10-01	2009-09-22	Dmi Life Sciences, Inc.	Metal-binding compounds and uses therefor
US7632803B2 (en)	1999-10-01	2009-12-15	Dmi Life Sciences, Inc.	Metal-binding compounds and uses therefor
EP1246618A1 (de) *	1999-12-21	2002-10-09	University Of Florida Research Foundation, Inc.	N,N'-Bis(2-hydroxybenzyl)ethylendiamin-N,N'-diessigsäure zur Behandlung mit Eisenchelatoren
US7160855B2 (en) *	2002-03-14	2007-01-09	Children's Hospital & Research Center At Oakland	Enhancement of iron chelation therapy
PL1866296T3 (pl) *	2005-04-04	2017-05-31	University Of Florida Research Foundation, Inc.	Polieterowe analogi desferritiocyny
JPWO2010032489A1 (ja)	2008-09-22	2012-02-09	国立大学法人旭川医科大学	鉄キレート剤及びその製造方法、並びに鉄イオンの定量・捕捉方法
WO2010133907A1 (en) *	2009-05-18	2010-11-25	Carlo Ghisalberti	Hexadentate chelators in inflammatory bowel disease
US20110077396A1 (en) *	2009-09-30	2011-03-31	General Electric Company	Intermediates for hydroxylated contrast enhancement agents
US20110077417A1 (en) *	2009-09-30	2011-03-31	General Electric Company	Intermediates for Hydroxylated Contrast Enhancement Agents
US8378134B2 (en) *	2009-09-30	2013-02-19	General Electric Company	Hydroxylated contrast enhancement agents
WO2012096183A1 (ja)	2011-01-14	2012-07-19	株式会社ダステック	高分子鉄キレート剤
WO2012104204A1 (en)	2011-01-31	2012-08-09	Vifor (International) Ag	Iron-carbohydrate complex compounds for the intravenous therapy of malaria
CN104706631A (zh) *	2013-12-14	2015-06-17	于莹莹	一种铁螯合剂作为制备抗癌药物的应用
US10472320B2 (en)	2015-06-25	2019-11-12	Nouryon Chemicals International B.V.	Process to prepare phenolic ethylenediamine diacetic acid compounds
US10093612B2 (en)	2015-06-25	2018-10-09	Akzo Nobel Chemicals International B.V.	Process to prepare phenolic ethylenediamine diacetic acid compounds

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3005848A (en)	1957-09-09	1961-10-24	Geigy Chem Corp	Ethylenediamine derivatives containing aromatic rings
US3758540A (en)	1968-02-13	1973-09-11	A Martell	Ferric chelates of n-(2-hydroxybenzyl) substituted aminopoly carboxylic acids
BE786946A (fr)	1971-07-29	1973-01-29	Ciba Geigy	Chelates pour combattre des symptomes de carences en metaux dans des systemes biologiques
GB1439048A (en)	1973-09-11	1976-06-09	Ciba Geigy Ag	Metal complexes of bis-azomethines and processes for their manufacture
FR2267308B1 (de)	1974-04-12	1976-10-08	Protex Manuf Prod Chimiq
CH602857A5 (de)	1976-12-10	1978-08-15	Ciba Geigy Ag
US4130582A (en)	1977-04-19	1978-12-19	Ciba-Geigy Corporation	Preparation of phenolic ethylenediaminepolycarboxylic acids
US4352751A (en)	1979-09-10	1982-10-05	Analytical Radiation Corporation	Species-linked diamine triacetic acids and their chelates
US4528196A (en) *	1981-02-23	1985-07-09	The United States Of America As Represented By The Department Of Health And Human Services	Chelating agents for the treatment of iron overload
US4647447A (en)	1981-07-24	1987-03-03	Schering Aktiengesellschaft	Diagnostic media
US4454106A (en)	1982-06-07	1984-06-12	Gansow Otto A	Use of metal chelate conjugated monoclonal antibodies
US4909257A (en)	1986-05-01	1990-03-20	The Regents Of The University Of California	Method for attaining in vivo tissue-specific contrast by nuclear magnetic resonance imaging
US5227474A (en) *	1987-02-13	1993-07-13	Abbott Laboratories	Bifunctional chelating agents
US5057302A (en) *	1987-02-13	1991-10-15	Abbott Laboratories	Bifunctional chelating agents
NZ231180A (en)	1988-10-31	1994-11-25	Dow Chemical Co	Bifunctional chelants;complexes,conjugates and pharmaceutical compositions thereof
US5376154A (en)	1991-05-13	1994-12-27	The Lubrizol Corporation	Low-sulfur diesel fuels containing organometallic complexes
US5840739A (en) *	1992-11-16	1998-11-24	University Of Florida Research Foundation, Inc.	Thiazoline acid derivatives
US5534241A (en) *	1993-07-23	1996-07-09	Torchilin; Vladimir P.	Amphipathic polychelating compounds and methods of use
AU1033495A (en) *	1993-12-16	1995-07-03	Ciba-Geigy Ag	N,n'-bis(2-hydroxybenzyl)ethylenediamine-n,n'-diacetic acid derivatives as chelating agents
US5539138A (en)	1994-07-28	1996-07-23	Merck Frosst Canada, Inc.	High affinity chelates containing isothiocyanate groups, useful for coupling with peptides and proteins
AU2958397A (en)	1996-05-21	1997-12-09	Novartis Ag	N,n'-di(2-hydroxybenzyl)ethylenediamine-n,n'-diacetic acid derivatives

1999
- 1999-02-03 AT AT99905716T patent/ATE285232T1/de not_active IP Right Cessation
- 1999-02-03 CA CA2319255A patent/CA2319255C/en not_active Expired - Fee Related
- 1999-02-03 PT PT99905716T patent/PT1052985E/pt unknown
- 1999-02-03 JP JP2000530205A patent/JP2002502816A/ja active Pending
- 1999-02-03 WO PCT/US1999/002388 patent/WO1999039706A1/en not_active Ceased
- 1999-02-03 TR TR2000/02256T patent/TR200002256T2/xx unknown
- 1999-02-03 NZ NZ506528A patent/NZ506528A/xx not_active IP Right Cessation
- 1999-02-03 CN CNB998027219A patent/CN1227006C/zh not_active Expired - Fee Related
- 1999-02-03 EP EP99905716A patent/EP1052985B1/de not_active Expired - Lifetime
- 1999-02-03 ES ES99905716T patent/ES2235461T3/es not_active Expired - Lifetime
- 1999-02-03 DE DE69922787T patent/DE69922787T2/de not_active Expired - Lifetime
- 1999-02-03 AU AU25814/99A patent/AU752383B2/en not_active Ceased
- 1999-12-21 US US09/467,943 patent/US6242492B1/en not_active Expired - Lifetime
2000
- 2000-11-28 US US09/724,823 patent/US6531510B1/en not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2319255C (en)	2010-01-26
PT1052985E (pt)	2005-04-29
ATE285232T1 (de)	2005-01-15
DE69922787D1 (de)	2005-01-27
DE69922787T2 (de)	2005-12-15
NZ506528A (en)	2002-11-26
EP1052985A1 (de)	2000-11-22
CN1227006C (zh)	2005-11-16
CA2319255A1 (en)	1999-08-12
JP2002502816A (ja)	2002-01-29
US6531510B1 (en)	2003-03-11
TR200002256T2 (tr)	2001-03-21
CN1290163A (zh)	2001-04-04
WO1999039706A9 (en)	2000-09-21
AU752383B2 (en)	2002-09-19
US6242492B1 (en)	2001-06-05
WO1999039706A1 (en)	1999-08-12
AU2581499A (en)	1999-08-23
EP1052985B1 (de)	2004-12-22

Publication	Publication Date	Title
CA2319255C (en)	2010-01-26	Pharmaceuticals comprising n,n'-bis(2- hydroxybenzyl) ethylenediamine-n, n'-diacetic acid for iron chelating therapy
US10071105B2 (en)	2018-09-11	Formulations of deoxycholic acid and salts thereof
US20070141162A1 (en)	2007-06-21	Injectable compositions for the controlled delivery of pharmacologically active compound
JP2010535198A (ja)	2010-11-18	コハク酸のコリン塩を含む鼻腔内投与用医薬品組成物
US20160354308A1 (en)	2016-12-08	Epinephrine-based ophthalmic compositions for intraocular administration and methods for fabricating thereof
JPS62158210A (ja)	1987-07-14	Ｌ−ド−パの直腸吸収形態
US20030216470A1 (en)	2003-11-20	Method for treating ileus
US20010039295A1 (en)	2001-11-08	N,N'-bis(2-hydroxybenzyl)-ethylenediamine-N,N'-diacetic acid in iron chelating therapy
US20050049210A1 (en)	2005-03-03	Methods for the controlled delivery of pharmacologically active compounds
CA3191276A1 (en)	2022-03-10	Ionic liquid formulations for treating diabetes
US20110046482A1 (en)	2011-02-24	Methods for reducing toxicities associated with medical procedures employing radiographic contrast agents
US9474763B2 (en)	2016-10-25	Compositions and methods for amelioration and prevention of drug-induced toxicity
AU2002254525B2 (en)	2004-12-23	Method for preventing acute renal failure
ES2719054T3 (es)	2019-07-08	Tratamiento de lesiones cutáneas asociadas a enfermedades autoinmunitarias e inflamatorias con el compuesto de arsénico As2O5
AU2002254525A1 (en)	2003-04-10	Method for preventing acute renal failure